A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma.

Trial Profile

A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Rilotumumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 21 Apr 2011 Status changed from active, no longer recruiting to discontinued.
    • 23 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 26 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top